TrumpRx Platform Launches With Mixed Savings on Prescription Drugs

The Trump administration rolled out a new website called TrumpRx in February 2026, aimed at offering consumers lower prices on certain prescription drugs. The platform lists discounted medications from more than a dozen drug companies, though it remains unclear how much it will lower costs for most Americans.

The website initially launched with 40 drugs, with the promise to add more. According to the administration, the platform uses "Most-Favored-Nation" pricing agreements negotiated with pharmaceutical manufacturers intended to align U.S. drug prices with the lowest prices paid by other developed nations. Administration officials say the website is aimed particularly at Americans who face high out-of-pocket costs for medications that are not fully covered by insurance.

The administration pointed to several examples of reduced prices, including medications used for diabetes, weight management, and fertility treatments. GLP-1 medications, among the highest-spending drug categories in the United States, are listed at substantially lower prices on the platform. Monthly prices for Ozempic are listed at an average of $350, down from more than $1,000, depending on dosage. Injectable Wegovy is listed at an average of $350, with some doses as low as $199. The pill form of Wegovy is listed as low as $149 per month. Zepbound is listed at an average of $346, with some doses as low as $299. On the site, a four-week supply of Wegovy injection pens costs $199 for the first two months and $349 after that, compared to the drug's list price of $1,349.02.

The administration also highlighted potential savings for Americans undergoing fertility treatment, noting that patients often pay out-of-pocket for these medications. Gonal-F is listed at prices as low as $168 per pen, depending on dosage. A single unit is listed on TrumpRx for $252, an 83% discount from its list price. Cetrotide is listed at $22.50, compared to a previous price of $316. Ovidrel is listed at $84, down from $251. Officials estimate some patients could save more than $2,000 per fertility treatment cycle under the new pricing structure.

TrumpRx does not sell medications directly. Instead, users are asked to print a coupon, which can be used at participating pharmacies. The discounted prices, the website says, are only available for "cash-paying patients," not those using insurance. The website advises, "If you have insurance, check your co-pay first — it may be even lower."

Congressional Democrats released a report showing that the new prescription drug website will lead families to spend thousands more on prescription drugs than necessary. While the website purports to offer families significant cost savings, in reality, many of the brand-name drugs listed on the site have much cheaper generic alternatives that are excluded from the TrumpRx website. This means that TrumpRx steers families to pay more when they could get the same medication at a much lower price.

Democrats on the Joint Economic Committee analyzed the prices of 15 common medications, comparing the discounted prices on the TrumpRx website to the cost of generics purchased using a discount coupon. The report shows, for instance, that a year's supply of the atrial fibrillation medication Tikosyn, purchased at the TrumpRx discounted rate, would cost about $4,000. By contrast, according to the report, a generic version of the drug bought with a discount coupon would cost just shy of $200 annually, a savings of roughly $3,800. The report uses Manchester, N.H., as the location for the search.

For Pristiq, used to treat depression, the TrumpRx platform's discounted rate clocks in at about $2,400 for an annual supply. An adult in Manchester, New Hampshire with depression who pays the TrumpRx price would spend $2,401.20 for a year of Pristiq when they could instead spend only $320.88 for a year of the cheaper generic option, a $2,080.32 cost increase. Similarly, an adult with high cholesterol who shops on TrumpRx would spend $2,771.21 for a year supply of Colestid when they could instead pay $856.70 for a year supply of the cheaper generic, a $1,914.51 cost increase.

The Democratic report also identified smaller cost disparities for some of the other drugs on the TrumpRx platform, such as Toviaz, used to treat an overactive bladder. According to the report, the price for one prescription of 30 pills runs about $44 at the TrumpRx discounted price, versus $40 for generics with a discount coupon. A year's supply of the drug Xigduo XR, used to help manage Type 2 diabetes, purchased using the TrumpRx discount would run about $908, according to the report. Generics with a discount coupon cost about $886.

A White House spokesperson accused Democrats of "resorting to idiotic or simply ignorant lines of attack instead of simply giving the president credit where it's due," arguing that while Democrats "spent decades talking about lowering prescription drug prices, President Trump actually delivered." The spokesperson added that "product listings on TrumpRx.gov are in no way an endorsement for use of any prescription drug over another," saying patients should check to see if the options on the site make "the most sense over other options." The spokesperson also noted that, because some products on the platform do not have generic competitors, the website "guarantees substantial savings" for Americans.

Health experts say the new site may not change what many people actually pay, as most Americans use insurance to cover prescriptions. A health economist at the University of Washington said that direct-to-consumer drug discounts are unlikely to help most patients. "Most patients have drug coverage. Very few are going to buy medications with cash, unless the drug is not a covered benefit, like weight loss or erectile dysfunction drugs." However, the discounts could matter for people without insurance, those with high deductibles or patients whose medications are not covered, including some weight loss and IVF drugs.

A Wisconsin pharmacist who has been practicing for 26 years said the program will have very little impact right now. Looking at the 43 drugs listed, many of them are products that have been available in generic form for many years. "It does sound good, because it's reducing the price of the brand-name (drugs), but nobody's using the brand-name. Everybody is getting the generic for $2, so it's not as good as it sounds." The pharmacist added, "But I'm still optimistic. I think that if they continue to work on finding the right manufacturers who are willing to work with them, they're going to find better solutions. But so far, I'm not very impressed."

The pharmacist explained that when it comes to brand-name medications, pharmacies have no negotiating power. "We have to go by what the wholesalers are telling us and it's usually a standard price." The biggest challenge is for people who are uninsured. "Most of the time, we're able to take care of them with some of the products that are already available in a generic form. But sometimes, they do need some of those expensive medications that don't have generics and they don't have an alternative. Those are the ones that actually cost a lot of money, and a lot of times, unfortunately, they get stuck, either by paying a lot of money to get them or going without them."

The White House said additional pharmaceutical companies are expected to join the platform through similar pricing agreements, with more high-cost medications added over time. The administration is also urging Congress to pass what it calls the "Great Healthcare Plan," which would codify the pricing model into law, expand price transparency requirements, lower insurance premiums, and allow purchases made through TrumpRx.gov to be covered under health insurance plans.

Meanwhile, drug prices continue to rise. A nonprofit research group said manufacturers raised list prices on 947 brand-name drugs in January 2026, while lowering prices on just 20. The median increase was about 4%, similar to last year and higher than inflation. Some prices have dropped sharply. The list price of the blood thinner Eliquis fell 43%, and Jardiance, a drug used to treat type 2 diabetes, dropped 44%. Both drugs were among the first selected for Medicare price negotiations under a Biden-era law.

Even so, overall prescription drug costs remain high. The Consumer Price Index for prescription drugs rose 2% between December 2024 and December 2025, and has fallen by less than 1% since January of last year.